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Abstract 
Background: Glucose-6-phosphate dehydrogenase deficiency (G6PDd), haemoglobin C (HbC) and S (HbS) are 
inherited blood disorders (IBD) common in populations in malaria endemic areas. All are associated to some degree 
with protection against clinical malaria whilst additionally G6PDd is associated with haemolysis following treatment 
with 8-aminoquinolines. Measuring the prevalence of these inherited blood disorders in affected populations can 
improve understanding of disease epidemiology. Current methodologies in epidemiological studies commonly rely 
on individual target amplification and visualization; here a method is presented to simultaneously detect the poly-
morphisms and that can be expanded to include other single nucleotide polymorphisms (SNPs) of interest.
Methods: Human DNA from whole blood samples was amplified in a novel, multiplex PCR reaction and extended 
with SNP-specific probes in an allele specific primer extension (ASPE) to simultaneously detect four epidemiologically 
important human markers including G6PD SNPs (G202A and A376G) and common haemoglobin mutations (HbS 
and HbC). The products were hybridized to magnetic beads and the median fluorescence intensity (MFI) was read on 
 MAGPIX® (Luminex corp.). Genotyping data was compared to phenotypical data generated by flow cytometry and to 
established genotyping methods.
Results: Seventy-five samples from Burkina Faso (n = 75/78, 96.2%) and 58 samples from The Gambia (n = 58/61, 
95.1%) had a G6PD and a HBB genotype successfully assigned by the bead-based assay. Flow cytometry data available 
for n = 61 samples further supported the concordance between % G6PD normal/deficient cells and genotype.
Conclusions: The bead based assay compares well to alternative measures of genotyping and phenotyping for 
G6PD. The screening is high throughput, adaptable to inclusion of multiple targets of interest and easily standardized.
Keywords: Malaria, Glucose-6-phosphate dehydrogenase deficiency, Haemoglobin S, Haemoglobin C, Multiplex 
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Background
Plasmodium parasites have co-evolved with human hosts 
and exert a considerable evolutionary pressure on muta-
tions that confer a degree of protection against malaria 
[1–5]. Examples of such mutations include polymor-
phisms in the X-linked glucose-6-phosphate dehydroge-
nase (G6PD) gene and in the HBB gene. G6PD is essential 
for the protection of cells against oxidative damage [6] 
and G6PD deficiency is common in malaria endemic 
areas [7] due to its association with protection of some 
manifestations of severe malaria [8]. The repertoire of 
G6PD deficiency molecular markers is extensive and 
displays considerable spatial heterogeneity [7, 9]. One of 
the most common G6PD variants in sub-Saharan Africa, 
the A− variant, requires two single nucleotide changes 
[10]. There are three common A− variants, an A376G 
substitution (present in all variants) may occur in com-
bination with G202A, T968C or A542T substitutions. In 
The Gambia for example, the combinations of A376G/
G202A, A376G/T968C and A376G/A542T are present in 
1.8%, 2.1% and 1% of the population, respectively, while 
the A376G/G202A variant and A376G without additional 
G6PD mutations are commonly found in Burkina Faso 
[11]. G6PD A− homo-/hemizygosity is associated with a 
pronounced 88% loss in enzyme activity whilst G6PD A+ 
is associated with only a mild 15% loss in enzyme activity 
[12]. The level of enzyme activity has consequences for 
the tolerability of some anti-malarial drugs; 8-aminoqui-
nolines can cause haemolytic anaemia in G6PD deficient 
individuals [13, 14].
Polymorphisms in the HBB gene, haemoglobin S 
(HbS, sickle cell trait) and haemoglobin C (HbC) pro-
tect against severe malaria [15]. The SNPs are located on 
chromosome 11 and result in the substitution of a gluta-
mate residue to a valine or lysine residue in the ß-globin 
chain, respectively. HbAS heterozygote sickle cell trait 
carriers have a selective advantage in malaria endemic 
regions as they are protected against severe malaria syn-
dromes [16]. Homozygous HbSS individuals, however, 
suffer from a serious blood disorder, sickle cell anaemia. 
Heterozygous HbAC individuals show some protection 
against severe malaria whereas homozygotes (HbCC) 
are strongly protected against malaria and, as opposed to 
HbSS homozygotes, only show symptoms of mild anae-
mia [17, 18]. Polymorphisms in the HBB gene may also 
increase the likelihood that malaria-infected individuals 
infect mosquitoes [18, 19].
Considering the implications conferred by human 
inherited blood disorders (IBD) on malaria disease 
risk and transmission potential, operationally attrac-
tive genotyping tools are of value. Current approaches 
typically assess a single IBD and whilst basic size elec-
trophoresis for HbC/HbS is practical, G6PD can require 
multiple PCR’s and visualizations on agarose gel. The 
assay described here simultaneously assesses four epi-
demiologically important human markers: G6PD G202A 
and A376G, HbS and HbC. Outcomes of the MagPlex-
TAG™ microsphere assay on samples from malaria-
exposed populations in Burkina Faso and in The Gambia 
are compared with established genotyping assays.
Methods
DNA from field samples
Study design and whole blood collection were performed 
as previously described [20]. Briefly, whole blood was col-
lected from males aged 18–45 years in Banfora (Burkina 
Faso) from August 2014 to November 2015 and from 
males aged over 10 years in Basse Santa Su, Upper River 
Region, The Gambia from December 2015 to April 2016. 
All participants were screened for glucose-6-phosphate 
enzyme activity using CareStart™ G6PD rapid diagnos-
tic test (G6PD RDT; Access Bio, Inc. Somerset, USA) and 
the Fluorescent Spot Test (FST) [21]. Both studies were 
conducted to investigate the safety of primaquine hence 
only males who had the G6PD enzyme activity measured 
by point-of-care tests were recruited. A small subset of 
samples (n = 6) from female participants was made avail-
able from another study in Burkina Faso [22] to test the 
assay on females.
DNA was extracted from 50 µl whole blood from Bur-
kina Faso using the Total NA High Performance kit on 
a MagNA Pure LC instrument (Roche, Switzerland) and 
eluted in 50  µl. DNA from The Gambia was extracted 
from 100 µl cryopreserved blood samples using the DNA 
Blood Mini kit (Qiagen, Germany) and eluted in 100 µl.
Assay optimizations
The assay required optimization at the PCR level, the 
allele specific primer extension (ASPE) level and the 
median fluorescence intensity (MFI) acquisition level. At 
the PCR level, the primer concentration (100–300  nM 
each), the annealing temperature (52.6–65.0 °C) and the 
template input volume (1–5  µl) were adjusted. At the 
ASPE level, annealing temperature (51.0 – 57.5  °C) and 
template volume (1–7 µl) were adjusted in addition to the 
Biotin-14-dCTP concentration (5–15  µM). At the MFI 
acquisition level the volume of ASPE product hybridized 
to beads (1–5 µl) and the concentration of SAPE conju-
gate (2.5–10  µg/ml) were adjusted. Bovine serum albu-
min (0.1%, BSA) was added before reading the plate on 
the MagPix to decrease buffer background MFI levels 
(Additional file 1: Table S1).
Genomic PCR amplification
The gene coding for glucose-6-phosphate dehydrogenase 
(G6PD) is located on the long arm of the X chromosome. 
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The gene contains multiple exons and the SNPs tested 
(G202A and A376G) are located on exons 5 and 6, 
respectively. The HBB gene is located on the short arm of 
chromosome 11 and the SNPs of interest (HbS and HbC) 
are located one base pair apart on exon 1 (Fig. 1a). Three 
fragments of 619 bp, 769 bp and 802 bp were amplified in 
the multiplex PCR reaction (Fig. 1b).
Five microliter of extracted DNA was amplified in a 
50 µl HotStarTaq Mastermix (Qiagen, Germany) reaction 
containing 100 nM (each) of G6PD primers and 300 nM 
(each) of HBB primers (Table 1). The G6PD primers were 
designed using Primer3 software. For the HBB amplifi-
cation, published primers were used [23]. After ampli-
fication, primers and nucleotides from the genomic 
PCR were removed by adding 3  µl ExoSAP-IT reagent 
(Applied Biosystems, USA) to 7.5 µl of PCR product.
Allele specific primer extension (ASPE)
Five microliter of cleaned PCR product was added to 
20  µl ASPE reaction mix containing 250  nM (each) of 
a
b
M   1  2   3   4    5    6    N   N  9  10  11 12 13 14  N  N    17 18 19 20 21 22 N N  
Condion 1 Condion 2 Condion 3
550 – 850 
Fig. 1 Genomic location and amplification of SNP targets. a Top: Representation of the multi-exon G6PD gene on the X chromosome. The G202A 
and the A376G markers are amplified by the primer pairs G202A Fw (forward)/G202A Rv (reverse) and A376G Fw (forward) and A376G Rv (reverse). 
The G202A allele specific primer extension (ASPE) probes (G202 and A202) anneal to the sense strand and either have a G or an A at their 3′ end 
(see red highlighted letters in brackets) and the A376G probes (A376 and G376) anneal to the sense strand and either have an A or a G at their 3′ 
end (see red highlighted letters in brackets). Bottom: Representation of the multi-exon HBB gene on chromosome 11. The HbS and HbC markers 
are amplified by the HBB prime pair. The HbS ASPE probes anneal to the sense strand and the HbC ASPE probes anneal to the anti-sense strand (see 
red highlighted letters in brackets). b G6PD and HBB amplification. Three primer concentrations were tested (conditions 1–3) on human positives 
(wells 1–22) and negative (N) controls. Condition 1 = equimolar primer concentration (200 nM each), condition 2 = 100 nM each of G202A and 
A376G primers and 300 nM each of HBB primers and condition 3 = 150 nM each of G202A and A376G primers and 300 nM each of HBB primers. 
Even numbered wells correspond to TA = 62.5 °C and odd numbered wells to TA = 60.2 °C. The HBB amplicon is 802 bp long (blue arrow), the G6PD 
A376G amplicon is 769 bp long (white arrow) and the G6PD G202A amplicon is 619 bp long (yellow arrow)
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ASPE probes and 200  µM Biotin-14-dCTP (Invitrogen, 
UK). The ASPE probes were designed using Primer3 soft-
ware and included the allele specific sequence at their 3′ 
end. The tag sequences and magnetic beads were cho-
sen according to the manufacturer’s recommendations 
(Table 1).
Hybridization and MagPix microsphere multiplex assay
Five µl ASPE reaction was hybridized to 2500 beads of 
each set, washed twice in 1 × Tm buffer (0.2  M NaCl, 
0.1 M Tris, 0.8% TritonX-100, pH 8.0) and incubated for 
15 min at 37 °C in 1 × Tm containing 0.1% bovine serum 
albumin (BSA) and 2.5  µg/ml Streptavidin, R-Phyco-
erythrin Conjugate (SAPE, Invitrogen, UK). Fifty µl of the 
reaction was read at 37 °C on a MagPix (Luminex corp., 
USA). The G6PD and HBB genotypes were called accord-
ing to net MFI of the wild type allele compared to the 
mutated allele (Additional file  1: Table  S3A and B). All 
field samples were repeated at least once. The assay was 
optimized on positive control DNA to maximize the fluo-
rescent signal and minimize background.
Flow cytometry for percentage (%) G6PD positive cells
In The Gambia, red blood cells (RBC) were cryopre-
served using established protocols [24, 25] and stored 
at − 80  °C (n = 61 samples, G6PD status confirmed by 
CareStart™ G6PD RDT, Additional file 2: Table S7). The 
samples were thawed and re-suspended in equal volume 
additive (2.5% glucose, 0.9% sodium chloride, 0.027% 
adenine, 0.75% mannitol) before measuring the % G6PD 
positive cells by a variation of the methaemoglobin test 
described in detail in [24, 26]. Samples were examined 
on a FACScailbur cytometer (Benson & Dickenson) (no 
gating, 10,000 events, in the FL1 channel 533 + − 30 nm). 
Analysis was conducted on FlowJo 10.1, and the SED 
(Super-Enhanced Dmax Subtraction Algorithm, FlowJo 
10.1, USA) was calculated. RBCs from anonymous blood 
donors from the London School of Hygiene and Tropical 
Medicine were used as controls.
Results
Multiplex HBB and G6PD genotyping on field samples
Seventy-five samples from Burkina Faso (n = 75/78, 
96.2%) and fifty-eight samples from The Gambia 
(n = 58/61, 95.1%) had a G6PD and a HBB genotype suc-
cessfully assigned by the bead-based assay (Fig. 2). Three 
samples from Burkina Faso and two samples from The 
Gambia were excluded due to net MFI values below the 
arbitrary cut-off of mean MFI plus two standard devia-
tions (mean MFI + 2SD) (Additional file 1: Table S2). This 
cut-off was chosen to unambiguously separate positive 
fluorescence signal from background signal. One sam-
ple from The Gambia failed to amplify in the initial PCR 
reaction. The G6PD and HBB genotypes of the remaining 
samples were called according to net MFI of the wild type 
allele compared to the mutated allele (Additional file  1: 
Table S3A and B). In Burkina Faso, the majority of sam-
ples (53.3%, 40/75) were HBB wild type and contained 
Table 1 Primers and Probes
PCR primer sequences and allele specific primer extension (ASPE) probe details. The top of the table contains the primers for genomic PCR amplification and the 
bottom part of the table contains the ASPE probes. The probe sequence that is complimentary to the anti-tag sequence coupled to the magnetic beads is highlighted 
in bold. The bead sets were chosen according to the Tag-It® Oligo Design Software v.3.00 (courtesy of Luminex corp., USA)
Genomic PCR primer
G202A Fw 5′GTG ACC TGG CCA AGA AGA AG3′
G6PD gene G202A Rv 5′AGG GAG GGA GGC CAAAG3′
A376G Fw 5′ACA CAC GGA CTC AAA GAG AGG3′
A376G Rv 5′GGG TCT GAG TGG CCT GAA G3′
HBB gene HBB Fw 5′GAG ATA TAT CTT AGA GGG AGGGC3′
HBB Rv 5′TTT CCC ATT CTA AAC TGT ACC CTG T3′
ASPE probes Sequence Bead set
202G 5′CTA AAT CAC ATA CTT AAC AAC AAA CCG AAA ACA CCT TCA TCG 3′ MTAG-A063
202A 5′ATA CTT TAC AAA CAA ATA ACA CAC CCG AAA ACA CCT TCA TCA 3′ MTAG-A019
376A 5′TTA ACA ACT TAT ACA AAC ACA AAC GCC TCA ACA GCC ACA TGA 3′ MTAG-A053
376G 5′ATC TCA ATT ACA ATA ACA CAC AAA GCC TCA ACA GCC ACA TGG 3′ MTAG-A067
HbA (C) 5′CTT AAA CTC TAC TTA CTT CTA ATT CAT GGT GCA TCT GAC TCC TG3′ MTAG-A056
HbC 5′AAC TTT CTC TCT CTA TTC TTA TTT CAT GGT GCA TCT GAC TCC TA3′ MTAG-A043
HbA (S) 5′CTA AAC ATA CAA ATA CAC ATT TCA CAG TAA CGG CAG ACT TCT CCT3′ MTAG-A062
HbS 5′AAT CAA CAC ACA ATA ACA TTC ATA CAG TAA CGG CAG ACT TCT CCA3′ MTAG-A048
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both the 202A and 376G SNPs (A−). Two samples con-
tained the 202A (mutation) SNP in the absence of the 
376G (mutation) SNP. HbAS was detected in 2.7% (2/75) 
and HbAC in 14.7% (11/75) of samples. Two individuals 
were homozygous HbCC.
In The Gambia, 32.8% (19/58) were HBB wild type and 
202G (wild type) and 376G (mutation, A+); HbAS was 
detected in 13.8% (8/58) and HbAC in 10.3% (6/58) of 
samples. Two individuals were heterozygous carriers for 
both the HbC and HbS alleles. Homozygous HbSS was 
not detected in either population.
To determine assay performance in G6PD normal or 
heterozygous female individuals, a small subset of sam-
ples (n = 6) from a separate study conducted in Burkina 
Faso [22] were tested. G6PD SNPs were successfully gen-
otyped in all samples irrespective of gender (Additional 
file 1: Table S4).
G6PD genotyping method comparison
The genotyping data generated here was compared to 
TaqMan OpenArray genotyping data [13] and KASP 
chemistry data [27] available for all samples (Burkina 
Faso, n = 78 and The Gambia, n = 61). Eight samples 
failed in the KASP assay and three samples failed in the 
TaqMan assay. The allele calls for all available samples 
agreed by all assays, only a single KASP genotyping call 
disagreed (data available for 139 sample pairs, Additional 
file 2: Table S6).
G6PD genotype and phenotype comparison
Sixty-one cryopreserved red blood samples from The 
Gambia (males only) were analysed by flow cytometry for 
percentage (%) G6PD positive cells, used here as a proxy 
of G6PD enzyme activity (Additional file  2: Table  S7). 
There were no indications of haemolysis in samples upon 
visual inspection. For four samples (4/61) the % of G6PD 
positive cells was below that of the negative controls and 
was set to zero. Flow cytometry results were stratified by 
G6PD genotype (Additional file 1: Figure S2). G6PD wild 
type samples (202G and 376A; n = 23) had the greatest % 
G6PD positive cells (median 89.5%, IQR, 77.1–93.7); defi-
cient A− samples (202A and 376G; n = 13) displayed the 
lowest % G6PD positive cells (median 2.37%, IQR 0.9–
16.7). The A+ samples (202A and 376G; n = 25, median 
G6PD positive cells 55.3%, IQR 4.81–79.4) contained 
two populations of cells: one similar to wild type sam-
ples (n = 17, median 72.3%, IQR 55.3–86.3) and the other 
similar to A− samples (n = 8, median 1.51%, IQR 0.005–
3.84). Interestingly, outliers were detected in the wild 
type populations and in the A− populations (Additional 
file  1: Figure S2). Three out of four wild type samples 
(0%, 22.5% and 40.3% G6PD positive cells respectively) 
with lower than expected % G6PD positive cells tested 
deficient by CareStart G6PD RDT. The fourth wild type 
outlier contained 26.0% G6PD positive cells and tested 
normal by CareStart G6PD RDT. The four A− samples 
with higher than expected % G6PD positive cells con-
tained 16.7%, 29.3%, 40.5% and 77.1% G6PD positive cells 
respectively and all four samples tested deficient by Car-
eStart G6PD RDT (Additional file 2: Table S7).
Genotyping data generated by PCR-based KASP chem-
istry was available for all samples with cryopreserved 
RBC data (n = 61, Sepulveda and Grignard, pers. comm., 
and [27]) and contained the two additional alleles com-
monly found in The Gambia; the Betica-Selma vari-
ant (T968C) and the Santamaria variant (A542T). The 
two alleles were only present in samples that also had 
the 376G mutation and the samples were hence classed 
as A− genotypes. The 376G/968C (n = 12) and the 
376G/542T (n = 4) mutations had a median % G6PD pos-
itive cells of 46.3% (IQR 1.5–64.0) and 52.3% (IQR 23.8–
70.4), respectively. Only nine samples were A+ (376G 
only) and these had a median % G6PD positive cells of 
86.3 (IQR 14.5–95.6). Now, only three A+ genotypes had 
low % G6PD positive cells, suggesting that some of the 
outliers in this group were explained by alternative SNPs 
(968C and 542T) affecting G6PD activity (Fig. 3).
Sample analysis and cost
Using the microsphere assay for the four markers, data 
for 96 samples was available within 7  h at an estimated 
Fig. 2 Summary of positive genotyping results of samples from 
Burkina Faso (n = 75) and The Gambia (n = 58). G6PD genotypes 
correspond to the 202A and 376G alleles (A−), the 202G and 376G 
alleles (A+), the 202A and 376A alleles (202 only) and the 202G and 
376A alleles (G6PDwt, wild type). The HBB genotypes are as follows, 
HbA corresponds to wild type homozygous, HbA/C corresponds to 
heterozygous A and C alleles, HbA/S corresponds to heterozygous A 
and S alleles, HbA/C/S corresponds to heterozygous A, C and S alleles 
and HbCC corresponds to homozygous CC alleles. No homozygous 
HbSS samples were detected in this study
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cost per sample of $ 4.30 (calculated December 2017, 
Additional file 1: Table S5). Standard protocols for G6PD 
and HBB genotyping involve a PCR reaction followed 
either by a restriction digestion (PCR–RFLP) or Sanger 
sequencing [23, 28]. The cost per sample for the four 
markers using standard protocols was estimated at $ 5.84 
per sample with 40 working hours processing time.
Discussion
This study describes a method for simultaneous assess-
ment of G6PD-deficiency markers and HBB polymor-
phisms. These were successfully genotyped from small 
volumes (5  µl) of DNA extracted from human blood. 
Gene segments were amplified in a single, multiplex PCR 
reaction and genotyped by magnetic bead-based allele 
specific multiplex assay. The assay is fast, relatively inex-
pensive and performed as well as established genotyping 
methods.
Assessing G6PD deficiency status is relevant to predict 
the susceptibility of individuals for the disadvantageous 
haemolytic consequences of treatment with 8-amino-
quinolines like primaquine and tafenoquine [29–33]. 
Although G6PD phenotyping assays [21, 34, 35] may be 
most informative in this respect and allow meaningful 
assessments of varying levels of G6PD due to random 
X-inactivation or lyonization [24–26, 36, 37], genotyping 
approaches are frequently used in population research to 
plan public health interventions [11, 38]. Here, a multi-
plex assay that concurrently detects common SNPs for 
the A− G6PD variant and HBB mutations was success-
fully developed using a mix of previously published and 
novel oligonucleotides [23] and optimized to maximize 
the SNP specific fluorescence signal. Using this micro-
sphere multiplex assay, samples from G6PD deficient 
and G6PD normal individuals were assessed for muta-
tions with good agreement with conventional genotyping 
methods. To assess the correlation in between G6PD gen-
otype and G6PD enzyme activity, the % G6PD-positive 
cells was assessed for different G6PD genotypes. In line 
with published data, the A− genotype (376G and 202A) 
had the lowest percentage G6PD positive cells compared 
to wild type and A+ individuals [39]. A small proportion 
of genetically deficient individuals did not have a lower 
percentage G6PD positive cells and, conversely, a frac-
tion of genetically G6PD normal individuals displayed 
unexpected low percentage G6PD positive cells. Includ-
ing additional SNPs that have been associated with lower 
G6PD activity in The Gambia [8], improved the correla-
tion between percentage G6PD positive cells and geno-
types. This suggests that genotyping approaches that 
focus only on 376G and 202A may misclassify individuals 
with low G6PD enzyme activity. The inability to explain 
all variation in G6PD activity by the examined SNPs sug-
gests that other (currently unidentified) genetic variants 
that affect G6PD status may exist.
The current genotyping results were based on popula-
tions enriched for G6PD deficient individuals and find-
ings thus do not represent G6PD deficiency prevalence 
in the two countries. Whilst the current selective sample 
set does not allow unbiased population prevalence esti-
mates, the HbS gene was more common in The Gambia 
than Burkina Faso (13.8% vs. 2.7%) and the HbC trait was 
more common in Burkina Faso (14.7% vs. 10.3%) [16, 40].
The assay presented here has an advantage that it can 
be adapted to multiple SNPs of interest and is increas-
ingly used for detecting SNPs associated with drug 
resistance in parasites [41, 42]. The assay does not 
detect large deletions such as either of the thalassaemias 
(α-thalassaemia and β-thalassaemia), which is one of its 
limitations. At present the assay contains two common 
G6PD SNPs and two HBB gene polymorphisms, but 
the flexible multiplex nature of the assay allows users to 
include additional markers. The assay is less time con-
suming and labour intensive than traditional end-point 
PCR/agarose gel genotyping methods and requires less 
operator time. Up to 50 markers can be tested in a single 
reaction and markers can be mixed and matched accord-
ing to population of interest and parasite epidemiology.
Conclusions
The microsphere multiplex assay presented in the current 
study may play a role in addressing the increasing need 
to test for human and parasite genetic changes because 
of their impact on disease progression and malaria 
Fig. 3 Percentage G6PD positive cells by flow cytometry by G6PD 
genotype. The % G6PD positive cells assessed by FACS was plotted 
against G6PD genotype generated by magnetic bead-based 
multiplex assay and KASP assay; wild type (wt, 202G and 376A), A+ 
(202G and 276G), A− (202A and 376G), A− (202A and 542TG) and 
A− (202A and 968C). The black horizontal line represents the median. 
The % G6PD positive cells were calculated using FlowJo version 10 
Super-Enhanced Dmax Subtraction (SED) algorithm
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epidemiology. The multiplex nature of the assay in addi-
tion to the fast turn-around time and the relatively low 
cost, make it attractive for assessment of multiple genetic 
markers in large-scale epidemiological studies.
Additional files
 Additional file 1: Table S1. Optimisation flow chart: A. Genomic PCR, 
B. ASPE (allele specific primer extension) and C. Hybridisation of ASPE 
reactions to microspheres. Optimal conditions in black. Table S2. Cut-off 
MFI values for each marker. The mean plus two standard deviations (Mean 
+ 2SD) of the background MFI signal of each marker was chosen as a 
cut-off value. An MFI signal greater than the cut-off scored a positive 
result. Table S3. Examples of how the net median fluorescence intensity 
(MFI) is recorded for each allele and the percentage wild type MFI (WT %) 
is calculated. A. For G6PD (G202A and A376G) in males (males only have a 
single copy of the G6PD gene), above 75% wild type MFI signifies that the 
sample is wild type and below 25% wild type MFI signifies that the gene 
carries a mutation. In males, if the percentage wild type MFI is between 
25%-75%, the genotyping needs to be repeated. In HBB (HbC and HbS), 
above 75% wild type MFI signifies homozygous wild type and below 
25% wild type MFI signifies a mutation on both alleles. A percentage wild 
type MFI and a percentage mutated MFI in between 25% and 75% signi-
fies that the sample is heterozygous and contains both a wild type and 
mutated allele. The G6PD genotypes are as follows: A- samples carry both 
the 202A and 376G mutations and the A+ samples carry the 202G wild 
type allele and the 376G mutation. B. The HBB genotypes can be either 
homozygous HbAA, HbCC or HbSS. Heterozygous genotypes contain 
a combination of genotyping calls, for example, HbA/C samples are 
heterozygous samples with a wild type allele (HbA) and a mutated HbC 
allele. This sample does not contain the HbS mutation on either of its two 
alleles. An HbA/C/S genotype is heterozygous for the both HbC and HbS 
alleles. Samples with net MFI values below the mean MFI plus two stand-
ard deviations (Mean + 2SD) for that marker are highlighted with a * (see 
Table S2). These samples were excluded from further analysis. Table S4. 
G6PD and HBB genotyping on samples from female participants. Six 
samples from females were analysed to show that the assay is working 
for homozygous and heterozygous women. Table S5. Pricing and time. 
Figure S1. Example of comparison of G6PD activity in normal (left) and 
deficient (right) individuals. The grey-shaded peaks correspond to samples 
and the blue-outlined peaks correspond to untreated negative controls. 
The log-10 fluorescence in the FL1 channel (533 ± 30 nm) is measured 
(x-axis). The SE Dmax % positive and the Overton % positive detect the % 
of positive cells against the control. The SE Dmax additionally accounts for 
outliers. Figure S2. Flow cytometry results by G6PD genotype. The per-
centage of G6PD positive cells was plotted by G6PD genotype generated 
by magnetic bead-based multiplex assay; wild type (wt, 202G and 376A), 
A+ (202G and 276G) and A- (202A and 376G). The % G6PD positive cells 
were calculated using FlowJo version 10 Super-Enhanced Dmax Subtrac-
tion (SED) algorithm. 
Additional file 2: Table S6. G6PD G202A & A376G genotyping compari-
son. The MagPix genotyping calls were compared to data generated by 
TaqMan OpenArray and KASP PCR-based genotyping. Wild type calls are 
202G and 376A, A- calls are 202A and 376G and A+ calls are 202G and 
376G. A dot (.) denotes samples for which genotyping was unsuccessful 
and samples marked with a * had low net MFI values (net MFI < net MFI + 
2SD). Table S7. G6PD percentage positive cells (G6PD % positive), geno-
typing amd CareStart G6PD RDT results for all samples from The Gambia. 
Samples were initially stratified by RDT result. The KASP genotypes 
include additional SNPs, T968C and A542T, that have been associated with 
decreased G6PD enzyme activity in The Gambia. The samples containing 
the mutant alleles are highlighted in green and the % G6PD positive cells 
are marked in green. Samples labelled with a * did not have a MagPix 
genotype assigned and hence had their KASP G6PD (G202A and A376G) 
used in this comparison.
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